Tag Archives: gene fusions

Identifying Genetic Mutations May Unlock Cure for Challenging Malignancies UCSF Benioff Children’s Hospitals have successfully treated a months-old infant...

Targeted next-generation sequencing of DNA has become more widely used in the management of patients with lung adenocarcinoma; however, no clear mitogenic driver alteration is found in some cases. Researchers at Memorial Sloan Kettering Cancer...

Molecular markers have become pivotal in brain tumor diagnostics. Mutational analyses by targeted next-generation sequencing of DNA and array-based DNA methylation assessment with copy number analyses are increasingly being used in routine...

The RNA-Seq technology has revolutionized transcriptome characterization not only by accurately quantifying gene expression, but also by the identification of novel transcripts like chimeric fusion transcripts. The ‘fusion’ or ‘chimeric’ transcripts have improved the diagnosis and prognosis of several tumors, ...

SeraCare Life Sciences, a global provider of tools supporting assay development and laboratory QC, and ArcherDX, a leading provider in next-generation sequencing-based assays, are announcing at the AMP Annual Meeting a partnership on the development and commercialization of highly multiplexed ...

The human genome is far more complex than thought, with genes functioning in an unexpected fashion that scientists have wrongly assumed must indicate cancer, research from the School of Medicine indicates. Hui Li, PhD, of the Department of Pathology and ...

Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of T-cell malignancies that generally demonstrate aggressive clinical behavior, often are refractory to standard therapy, and remain significantly understudied. The most common World Health Organization subtype is PTCL, not otherwise specified (NOS), ...

Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of T-cell malignancies that generally demonstrate aggressive clinical behavior, often are refractory to standard therapy, and remain significantly understudied. The most common World Health Organization subtype is PTCL, not otherwise specified (NOS), ...

Cambridge, UK, 22 March 2016: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), the leading international gene editing company supplying tools and services that power genomics research and the development of personalized medicines today announces the launch of ...

A multi-institution research group jointly led by Professor Jan Prins and UNC CS alumna Professor Jinze Liu at the University of Kentucky is developing algorithms and software to analyze RNA using high-throughput sequencers. The software is in use in multiple ...